ERBB2 and breast cancer: The main finding emerging from this study was that in HER2+ breast cancer, a high CD163+ TAM count was strongly associated with an inferior outcome; it remained a strong independent prognostic factor across all the investigated survival endpoints and regardless of the hormone receptor status, while there were no significant associations with survival in the HER2− cohort.